Here are seven key points:
1. In 2013, Pfizer asked the FDA to ban Depo-Medrol for epidural use, citing the risk of blindness, stroke, paralysis and death. Neither Pfizer nor the FDA publicized the request.
2. While the FDA did not issue a ban, opting instead to increase the label warning, several other countries granted Pfizer’s request.
3. In June, the U.S. House of Representatives approved an increase in Medicare reimbursement for the Depo-Medrol injectable spinal procedure.
4. According to the health data firm IQVIA Institute for Human Data Science, total sales of brand name and generic Depo-Medrol grew 35 percent over two years, from $133 million in 2015 to $185 million in 2017.
5. An FDA records review found 2,442 serious problems reported from Depo-Medrol injections between 2004 through March 2018, including 154 deaths.
6. According to Pfizer spokesman Thomas Biegi, Pfizer the company cannot stop off-label Depo-Medrol shots without an FDA ban.
7. The cost per shot varies from $100 to $800 with an additional fee to the hospital or clinic where it is administered fee.
More articles on practice management:
Medicare reconsiders paying for spine surgeries at ASCs: 4 insights
Good Samaritan Hospital embarks on $9M upgrade of orthopedic surgery & bariatric units: 3 notes
State-by-state breakdown: 28 new practices to open in 2018
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
